NYSE: $BMY A Significant Milestone in Cancer Treatment Recent clinical trial data has brought encouraging news for patients fighting advanced cancers. The investigational therapy izalontamab brengitecan (Iza-Bren) has demonstrated significant efficacy, effectively doubling the median progression-free survival (PFS) in patients who have previously undergone multiple lines of treatment. Understanding the Impact For patients facing recurring…